Navigation Links
Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Date:12/9/2009

lopment and expedite the review of drugs that treat serious diseases and fill an unmet medical need based on the need for safer non-invasive tests to diagnose pancreatic disorders. There are more than 300,000 MRI procedures conducted in the U.S. and Europe each year that could directly benefit by the addition of RG1068.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statem
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
2. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
3. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
4. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
5. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
8. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
9. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
10. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
11. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)...  EndoChoice today announced the launch of its initial ... which will represent 25.6% of its outstanding common stock ... corporation in connection with the offering. The initial ... $15 and $17 per share. The underwriters for the ... up to an additional 937,500 shares of EndoChoice common ...
(Date:5/26/2015)... LONDON , May 26, 2015 ... that technology,s commercial potential ,What,s the future of ... and commercial predictions from 2015. Stay ahead there ... tests, you explore sales results, R&D, opportunities and ... visiongain shows you what,s possible for ...
(Date:5/26/2015)... , May 26, 2015  Array BioPharma ... its Chief Executive Officer, Ron Squarer , ... Conference in New York City. The public is welcome ... on the Array BioPharma website.Event: Jefferies 2015 Global ... 2015Time:1:30 p.m. Eastern Time Webcast: www.arraybiopharma.com  About Array ...
Breaking Medicine Technology:EndoChoice Announces Launch of Its Initial Public Offering 2Cell-Based Assays: World Industry and Market Prospects 2015-2025 2Cell-Based Assays: World Industry and Market Prospects 2015-2025 3Cell-Based Assays: World Industry and Market Prospects 2015-2025 4Cell-Based Assays: World Industry and Market Prospects 2015-2025 5Cell-Based Assays: World Industry and Market Prospects 2015-2025 6Cell-Based Assays: World Industry and Market Prospects 2015-2025 7
... WIRE)--Jun 25, 2007 - HepaLife Technologies, Inc.,(OTCBB: ... that new,data presented at an international influenza ... line outperforms,current cell technologies at replicating human ... step towards the production of,a cell-culture based ...
... of patients receiving highest dose,achieves A1c with ... /PRNewswire-FirstCall/ -- According to,findings presented today at ... Association (ADA) in Chicago, Illinois, the,investigational treatment ... analog under development by Novo Nordisk for ...
Cached Medicine Technology:HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 2HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 3HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 4HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 5HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 6Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 2Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 3Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 4
(Date:5/26/2015)... 2015 National Prevention Week , National ... It is supported by the Substance Abuse and Mental ... awareness of, and action about, substance abuse as well ... coalitions are encouraged to join in promoting prevention strategies, ... issues, and in building community partnerships. , The Voice ...
(Date:5/26/2015)... 2015 i2i Systems, the leader in ... than 15 years, has earned 2014 Patient Centered Medical ... Assurance (NCQA) for its flagship product i2iTracks , ... the work we have done to create healthier populations ... acknowledgement from NCQA once again,” said Janice Nicholson, co-founder ...
(Date:5/26/2015)... New York, NY (PRWEB) May 26, 2015 ... show for a good cause. "The photography show will connect ... difference in their lives.” For the last five years, Raul ... pictures to convey the notion that we are not bounded ... Quechua, a language spoken in Raul’s native country, Bolivia. The ...
(Date:5/26/2015)... 2015 Adenna, Inc ., worldwide ... excited to announce the launch of Enov8 ... made of polyethylene (PE) and approved by the U.S. ... , The Enov8 glove might look like ... mixing salads but our proprietary formula and production technology ...
(Date:5/26/2015)... Viejo, CA (PRWEB) May 26, 2015 ... styles for Final Cut Pro X . ... suspenseful to simple and elegantly styled text. , ... in seconds. , ProTrailer Network can easily complement any ... style desired and within seconds can make professional looking ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Takes Part in National Prevention Week 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 3Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 2Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 3Health News:A Photographer & Two Educational Organiazations Join to Make a Difference in Our Youth 2Health News:Enov8® Exam Glove by Adenna® Approved by U.S. FDA 2Health News:Developers at Pixel Film Studios Release ProTrailer Network for Final Cut Pro X 2
... A latest men’s health survey has revealed that men over ... in their 30s or 40s. Their level of satisfaction approximates ... interesting study are published in the February issue of BJU ... 185 Norway men ranged between 20 and 79 years of ...
... Tinnitus is a problem where people are plagued all round their ... from it since she was three. She describes it as the ... a metal spiral staircase. After 25 years later she says that ... an exhibition designer tells that it drives her crazy. Statistics show ...
... UK. The recent reports that many women will be barred from ... caused a lot of commotion among them. // ... 13,000 deaths are expected. But recently the Association of British Insurers ... genetic breast cancer tests. , But it was also ...
... logs, maintained by teenagers from age 13 to 17, ... personal information, //thus making them vulnerable to cyber stalking ... in the technology and social behavior program, will be ... American Association for the Advancement of Science in St. ...
... Immune cells destroy the myelin sheath that surrounds nerve ... myelin is very essential in transmitting the impulses across the ... the metals aluminium and iron in the urine of people ... said that MS could be linked to difficulty in processing ...
... that the euthanasia campaigner Dr Philip Nitschke does not possess ... ,The workshop informs participants of their legal rights about ending ... to be registered as a doctor to carry out his ... denies that he needs a licence. He faces a criminal ...
Cached Medicine News:Health News:50 Plus Men More Satisfied With Sex Life 2Health News:Tinnitus: a problem which is still ambiguous 2Health News:Health insurance in the future would depend on genetic test results 2Health News:Teens need to Exercise Caution While Using Online Blogs 2Health News:Aluminium and Iron Could Play a Vital Role in Multiple Sclerosis 2
... to remove a cast from an arm or ... patients are cut or burned by the cast ... professionals to remove any cast with confidence. This ... cuts and burns from the cast saw and ...
... choice plays an important part in ... particularly where reduced capsule formation, inflammation ... considerations. GORE-TEX Suture, a nonabsorbable, ePTFE ... characteristics sought by a variety of ...
... GORE-TEX ACUSEAL Cardiovascular Patch ... it to "seal" around penetrating ... bleeding by as much as ... with improved suture retention, multi-directional ...
... Vascular Grafts have met the challenges ... Recognized for exceptional performance and quality, ... renowned surgeons worldwide. These grafts require ... spread of infection, and ensure utmost ...
Medicine Products: